for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Avenue Therapeutics Inc

ATXI.OQ

Latest Trade

5.65USD

Change

-0.13(-2.25%)

Volume

7,602

Today's Range

5.64

 - 

5.74

52 Week Range

4.21

 - 

7.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Avenue Therapeutics Reports Third Quarter 2019 Financial Results And Recent Corporate Highlights

Nov 4 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.14.Q3 EARNINGS PER SHARE ESTIMATE $-0.28 -- REFINITIV IBES DATA.QTRLY CASH AND CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $13.7 MILLION, COMPARED TO $15.5 MILLION AT JUNE 30, 2019.NET LOSS FOR THREE MONTHS ENDED SEPTEMBER 30, 2019 WAS $0.14 PER SHARE.AVENUE THERAPEUTICS- LOOKING AHEAD, ON TRACK TO SUBMIT A NEW DRUG APPLICATION FOR IV TRAMADOL TO U.S. FDA BY YEAR-END 2019.

Avenue Therapeutics Q2 Loss Per Share $0.43

Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.43.Q2 EARNINGS PER SHARE ESTIMATE $-0.48 -- REFINITIV IBES DATA.

Avenue Therapeutics Says Second Pivotal Phase 3 Trial Of IV Tramadol Achieved Primary Endpoint

June 3 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE DATA FROM SECOND PIVOTAL PHASE 3 STUDY OF INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - SECOND PIVOTAL PHASE 3 TRIAL OF IV TRAMADOL ACHIEVED PRIMARY ENDPOINT.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL..

Avenue Therapeutics Q1 Loss Per Share $0.82

Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $0.82.Q1 EARNINGS PER SHARE ESTIMATE $-0.43 -- REFINITIV IBES DATA.AS OF MARCH 31, 2019, AVENUE'S CASH AND CASH EQUIVALENTS TOTALED $29.4 MILLION, COMPARED TO $2.7 MILLION AT DECEMBER 31, 2018.

Avenue Therapeutics Q3 Loss Per Share $0.25

Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q3 LOSS PER SHARE $0.25.

Avenue Therapeutics Reports Q2 Loss Per Share $0.45

Aug 14 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q2 LOSS PER SHARE $0.45.AS OF JUNE 30, 2018, AVENUE'S CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $8.9 MILLION.

Avenue Therapeutics Reports Positive Topline Phase 3 Data For Intravenous Tramadol In The Management Of Postoperative Pain

May 21 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS ANNOUNCES POSITIVE TOPLINE PHASE 3 DATA FOR INTRAVENOUS TRAMADOL IN THE MANAGEMENT OF POSTOPERATIVE PAIN.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - IV TRAMADOL ACHIEVED PRIMARY AND KEY SECONDARY ENDPOINTS, AS WELL AS A CLEAR DOSE RESPONSE.AVENUE THERAPEUTICS INC - INITIATION OF SECOND PIVOTAL PHASE 3 TRIAL PLANNED FOR Q3 OF 2018.AVENUE THERAPEUTICS INC - IV TRAMADOL WAS WELL-TOLERATED WITH NO REPORTS OF DRUG-RELATED SERIOUS ADVERSE EVENTS IN TRIAL.AVENUE THERAPEUTICS INC - IV TRAMADOL 25 MG TREATMENT ARM GENERALLY DISPLAYED INTERMEDIATE RESULTS THAT FELL BETWEEN 50 MG AND PLACEBO ARMS.AVENUE THERAPEUTICS - ANTICIPATE FILING NDA FOR IV TRAMADOL WITH U.S. FDA IN LATE 2019.

Avenue Therapeutics Reports Q1 Loss Per Share Of $1.03

May 3 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q1 LOSS PER SHARE $1.03.AS OF MARCH 31, 2018, CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS TOTALED $15.0 MILLION.

Avenue Therapeutics Files For Mixed Shelf Offering Of Up To $75 Mln

April 13 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS FILES FOR MIXED SHELF OFFERING OF UP TO $75 MILLION - SEC FILING.

Avenue Therapeutics Reports Q4 Loss Per Share $0.63

March 1 (Reuters) - Avenue Therapeutics Inc <ATXI.O>::AVENUE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS.Q4 LOSS PER SHARE $0.63.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up